Literature DB >> 23535946

[Erlotinib-induced acneiform eruption].

R U Wahl1, M Megahed.   

Abstract

A 73-year-old man has been suffering from a pulmonary adenocarcinoma for three years. He has been treated with the EGF-inhibitor erlotinib for the past 18 months. While taking this medication he developed a progressive papulopustular rash on his face and trunk which later spread to his thighs. Topical treatment with methylprednisolone and nadifloxacin, as well as short courses of systemic doxycycline and ciprofloxacin, led to marked improvement and control of his skin condition.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23535946     DOI: 10.1007/s00105-013-2551-z

Source DB:  PubMed          Journal:  Hautarzt        ISSN: 0017-8470            Impact factor:   0.751


  4 in total

1.  Disappearing breast cancers.

Authors:  S A Narod
Journal:  Curr Oncol       Date:  2012-04       Impact factor: 3.677

Review 2.  Cutaneous side effects of new antitumor drugs: clinical features and management.

Authors:  Ralf Gutzmer; Andreas Wollenberg; Selma Ugurel; Bernhard Homey; Arnold Ganser; Alexander Kapp
Journal:  Dtsch Arztebl Int       Date:  2012-02-24       Impact factor: 5.594

3.  Periodontal status of HIV-infected patients undergoing antiretroviral therapy compared to HIV-therapy naive patients: a case control study.

Authors:  Ulrich Fricke; Werner Geurtsen; Ingmar Staufenbiel; Alexander Rahman
Journal:  Eur J Med Res       Date:  2012-01-30       Impact factor: 2.175

Review 4.  Clinical practice guidelines for the prevention and treatment of EGFR inhibitor-associated dermatologic toxicities.

Authors:  Mario E Lacouture; Milan J Anadkat; René-Jean Bensadoun; Jane Bryce; Alexandre Chan; Joel B Epstein; Beth Eaby-Sandy; Barbara A Murphy
Journal:  Support Care Cancer       Date:  2011-06-01       Impact factor: 3.603

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.